Fig 1.
Flowchart of participants through each stage of the study “Low versus high dose of antimony for American cutaneous leishmaniasis.”
Fig 2.
Different stages of the wound healing process in American cutaneous leishmaniasis.
Table 1.
Baseline demographic and clinical characteristics of the modified intention-to-treat population.
Table 2.
Primary and secondary outcomes.
Fig 3.
Non-inferiority plot of low dose antimony versus high dose antimony for American cutaneous leishmaniasis.
Data are shown as point estimates and 90% confidence interval (CI) for absolute risk difference in clinical cure for intention-to-treat and per-protocol populations. Non-inferiority can be established if confidence intervals are within the prespecified boundary for non-inferiority (Δ).
Fig 4.
Bubble plot of -log10(Raw p-value) by risk difference with a two-sided 95% confidence interval sized by number of subjects with adverse events in high dose versus low dose antimony groups.
Note: Grey zone area corresponds to area of p-value<0.05; X stands for point estimates; point estimates within the grey zone area have p-values<0.05; circles are sized by the number of patients with adverse events; circles located to the right of the vertical solid line favor more adverse events in the high dose antimony group.
Fig 5.
Subgroup analysis: Forest plot of absolute risk difference (RD) and relative risk (RR) with two-sided 95% confidence interval (CI) for major adverse events according to low versus high dose antimony treatment.
Squares located to the right of the vertical solid line favor more major adverse events in the high dose antimony group.